Introduction {#S1}
============

Obesity is a medical and social serious condition regarding the public health ([@B22]). Beyond obesity among the adult population, the great increase of obese and overweight children and adolescents worldwide is worrying ([@B37]; [@B22]). Obesity is characterized by errate energy imbalance. Very often physical inactivity contributes to this imbalance. Both a hypocaloric diet and physical activity may play roles in achieving energy balance goals or may prevent the onset of the imbalance ([@B148]; [@B58]; [@B8]; [@B59]; [@B140]).

Obesity is accompanied by deregulation of other metabolic parameters such as worse lipid profiles, increased insulin resistance, and a pro-inflammatory state. In addition, cytokines secreted by adipose tissue, called adipokines, strongly contribute to the establishment and progression of obesity ([@B14]; [@B24]). These cytokines physiologically control many metabolic pathways; for these reasons, their production may change according to physio-pathological conditions. During obesity, different adipokines are secreted in altered concentrations. It remains an open question if adipokine deregulation is a cause or a consequence of metabolic alterations. Among others, Adiponectin is a relevant adipokines, considering its strong insulin sensitizing, hypoglycemic and anti-inflammatory power ([@B38]; [@B10]).

Adiponectin concentrations are strongly reduced in obesity; lower Adiponectin levels in obese patients are related to several deleterious metabolic changes ([@B115]). Adiponectin levels increase with weight loss and improved insulin sensitivity ([@B143]; [@B115]; [@B2]; [@B129]).

Both a hypo-caloric diet and physical exercise can increase insulin sensitivity, improving lipid profiles and reducing the inflammatory state. It has also been proved in obese adults that weight loss induced by diet is associated with an improvement in Adiponectin levels. On the contrary, the beneficial effects of physical exercise is associated with insulin sensitivity associated with an increase in plasma Adiponectin concentrations, even if this concept has not been completely clarified ([@B2]). Recent studies in lean subjects have provided inconsistent evidence, reporting both unchanged and increased Adiponectin levels after exercise. Nevertheless, it was demonstrated that Adiponectin has anti-diabetic, antiatherogenic, anti-inflammatory and insulin-sensitizing properties ([@B166]; [@B1]; [@B11]; [@B142]). Therefore, the identification of different strategies such as physical activity able to up-regulate the expression of Adiponectin and/or to enhance the action of Adiponectin could strongly contribute to mitigate or minimize metabolic dysfunctions.

Another important mediator related to obesity development is Orexin-A/Hypocretin 1, a neuropeptide synthesized in the lateral hypothalamus ([@B99]; [@B147]). It plays an important role in the regulation of appetite: indeed, a reduction in the amount of Orexin-A determines a reduction of appetite ([@B64]; [@B102]; [@B26]). An intracerebroventricular injection of Orexin-A modifies eating behavior, increasing heart rate, blood pressure, and metabolic rate. Orexin-A acts on the arched nucleus of the hypothalamus, stimulating food intake, hunger, and hypoglycemia ([@B101], [@B100]). This neuropeptide plays an important role in the regulation of metabolic rate. It is commonly thought that Orexin-A causes an increase in the thermoregulation setpoint, generating modifications in body temperature perception and changing food intake habits. Orexin-A modulates energy metabolism, excitement, and physical activity, playing a pivotal role fighting obesity, and thermogenesis during non-exercise activities, as well as energy expenditure ([@B136]). Many studies conducted on knockout mice for Orexin-A have shown that these mice become obese, consuming fewer calories than the wild type. This pathological state is probably due to the energy imbalance caused by reduced physical activity. On the other hand, if Orexin-A was administered through injections, particularly in the rostral lateral hypothalamus of these mice, they showed a weight loss, developing a greater propensity for spontaneous physical activity, increasing energy expenditure and diminishing food intake ([@B45]; [@B29]; [@B42]). The positive effects on physical activity are evident a few minutes after assimilation, while the effects on weight loss are delayed. The strong connection between Orexin-A levels and obesity-consequences, candidates this neuropeptide as an interesting element for the fight against obesity. In obese men, it has been well described that low levels of circulating Orexin-A are related to the diminished response of its receptors in fatty tissues ([@B108]). It is now clear that moderate aerobic exercise has a positive effect on health and body weight, as well as on increasing cognitive abilities. Moreover, Orexin-A levels regulate the concentration of glucose: hyperglycemia could be caused by an insufficient Orexin-A signal, blocking physical activity and promoting an overweight state ([@B21]; [@B36]; [@B108]).

In this review, we aimed to analyze the interconnections among Adiponectin, Orexin-A levels, and physical activity and to describe the state of the art on Adiponectin and Orexin-A as natural factors improving healthy status through physical exercise.

The Adiponectin {#S2}
===============

Adiponectin: Structural Characteristics {#S2.SS1}
---------------------------------------

Adiponectin produced by visceral and subcutaneous adipose tissue; in particular, its production and secretion are induced ≈100-fold during adipocyte differentiation. Recently, other relevant Adiponectin sources have been described: - Bone marrow adipose tissue, - Endothelial cells, - Lymphocytes ([@B97]).

The encoding gene for Adiponectin is the APM1 gene (also known as GBP28). APM1 maps to chromosome 3q27, a genomic region that has been linked to susceptibility to diabetes and metabolic syndrome ([@B70]; [@B143]). Many data literature described the association between APM1 polymorphisms and increased incidence and susceptibility to metabolic disorders, but these data are still ambiguous. Nevertheless, several data have been produced about the effects of SNPs (single-nucleotide polymorphisms) in the APM1 gene on Adiponectin serum concentrations ([@B175]; [@B85]). The resulting protein is a 244 amino acid open reading frame containing 4 domains, a short N-terminal region, a hypervariable region with no homology to any known protein domain (secretory signal sequence of 66 amino acids), a collagen-like domain (Gly-*X*-*Y* repeats), and a C-terminal globular domain that presents a high homology to C1q ([@B70]; [@B143]). Within the globular domain, there is a high degree of sequence conservation, suggesting that this domain is essential for preserving biological function. Adiponectin belongs structurally to the soluble defense collagen superfamily sharing significant homology with collagen X, VIII and the complement factor C1q ([@B160]).

Furthermore, Adiponectin is regulated by post-translational modifications such as hydroxylation and glycosylation. Hydroxylation concerns four conserved proline residues in the collagenous domain and eight lysine residues; these latter subsequently undergo glycosylation. These modifications are crucial to initiate the process of oligomerization into several characteristic oligomeric isoforms, including trimeric, hexameric, and the HMW oligomeric complexes. It is very interesting to note that the oligomerization process is essential in determining Adiponectin functions and that once released from adipocytes, oligomers are not interchangeable ([@B153]). Through hydrophobic interactions, three globular domains form a globular head ([@B160]), and simultaneously the three collagenous domains form a triple-helical structure that appears as the stick of the Adiponectin trimer ([@B153]; [@B161]). The trimers represent the building block for the association of Adiponectin in higher molecular weight structures.

The trimers correspond to low molecular weight (LMW) Adiponectin ([@B153]; [@B161]), hexamers to medium molecular weight (MMW) Adiponectin and the octamers or more significant oligomers correspond to HMW species, are the three significant Adiponectin oligomers present in serum ([@B152]; [@B149]; [@B72]). Human HMW Adiponectin is composed of multiple species, ranging from 18--30-mers or even larger molecular mass species, whereas murine HMW Adiponectin contains only the octadecamers. Many scientific data have provided evidence that distinct Adiponectin oligomers carry out specific functions. The three primary oligomeric forms of Adiponectin appear to differ in their metabolic actions as follows: HMW or trimeric Adiponectin could lower blood glucose ([@B153]; [@B161]; [@B35]; [@B48]) and activate AMP-activated protein kinase (AMPK) in various tissues ([@B48]), the hexamer does not appear to be as metabolically active as HMW. Moreover, a hypothesis that HMW Adiponectin may represent a storage form of trimers has been developed; according to this hypothesis, an extracellular reductase converts HMW species to trimers. However, there is no evidence that there is a strict association between total and HMW Adiponectin in circulation ([@B122]; [@B87]; [@B53]). Once produced, Adiponectin is abundantly secreted, accounting for about 0.01% of total plasma protein. Both in humans and rodents, Adiponectin presents a sexual dimorphism being higher in women than in men ([@B90]). The lower plasma levels of total Adiponectin in males are mainly due to the selective reduction of HMW oligomers, effects due to testosterone that has inhibiting effects on the secretion of this oligomeric complex from adipocytes ([@B70]).

Adiponectin Receptors {#S2.SS2}
---------------------

Adiponectin exerts its multiple biological effects throughout the body, mediated by the specific receptors AdipoR1, AdipoR2, and T-cadherin. The human AdipoR1 gene is located at chromosome 1p36.13-q41, whereas AdipoR2 is located at chromosome 12p13.31. Both AdipoR1 and AdipoR2 are structurally distinct from most other 7TM proteins, because of their extracellular located C-terminus and cytosolic N-terminus ([@B70]; [@B75]). These receptors, which share 67% amino acid identity, activate several signaling pathways through the help of adaptor proteins ([@B170]; [@B94]). Among others, APPL1 has been identified as an AdipoR1 and AdipoR2 binding protein. The N-terminal amino acids (4--142) of AdipoR1 interact with APPL1. Adiponectin enhances the formation of the AdipoR1 APPL1 complex ([@B94]). The precise mechanisms by which APPL1 mediates Adiponectin signaling remain largely unknown; APPL1 probably contains multiple potential phosphorylation sites. Recently, [@B151] reported the crystal structures of human AdipoR1 and AdipoR2 at 2.9 and 2.4 Å resolution, respectively. An exciting feature of these receptors is that they seem to form dimers and oligomers, even if the exact nature of the oligomers and their functional meaning have not been clarified yet. AdipoR1 is conserved from yeast to man, especially in the seven transmembrane domains. Although AdipoR1 expression is predominant in muscle while AdipoR2 is most abundantly expressed in the liver, both receptors are widely expressed in many cell types and tissues ([@B104]). Moreover, the two receptors have preferable signaling pathways: AdipoR1 mainly induces the phosphorylation of AMP-activated protein kinase (AMPK), whereas AdipoR2 predominantly activates the peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG) ([@B175]). However, to date, the signaling pathways of the two receptors, have not been fully clarified. It has been shown that AdipoRs are also capable of activating ERK1/2 phosphorylation, the phospholipase Ca2/calmodulin-dependent protein kinase pathway, and ceramidase activity ([@B104]).

The expression levels of AdipoR1 and AdipoR2 mRNA expression are regulated by several factors. In the liver and skeletal muscle, they are increased after fasting, and are rapidly restored after refeeding; AdipoR levels increase in the liver in the course of hypoinsulinemia and hyperglycemia, decreasing in adipose tissue and muscle. Insulin treatment reduces AdipoRs expression. The reduced expression levels of AdipoRs in muscle and liver in obesity are associated with reduced expression of AdipoR1/R2, and therefore to a weak Adiponectin signaling ([@B158]). The decreased plasma levels of Adiponectin that in turn cause a decrease in AdipoRs levels in obesity, lead to insulin resistance and to a status of reduced Adiponectin sensitivity, the so-called "vicious cycle." Independently of AMPK, Adiponectin stimulates a ceramidase activity associated with its two receptors, enhancing ceramide catabolism and formation of sphingosine-1-phosphate (S1P) ([@B60]). Stimulation of ceramidase activity has multiple beneficial metabolic and insulin-sensitizing effects, whereas S1P is a second messenger with well-known anti-inflammatory and anti-apoptotic functions ([@B157]). The interchangeable balance in the cellular levels of ceramides and S1P controls many processes as cellular apoptosis and proliferation ([@B61]; [@B157]).

The third Adiponectin receptor is T-cadherin, a glycosylphosphatidylinositol (GPI) that is anchored to the surface membrane and lacks the cytoplasmic domain. This receptor is not adequately expressed in muscle and liver but is expressed in vascular endothelial and smooth muscle cells. Since T-cadherin does not have an intracellular domain, it is unclear whether it can behave as an Adiponectin receptor, but rather it may be an Adiponectin-binding protein. Probably, it merely acts as a depot of Adiponectin, similar to a decoy receptor ([@B172]). The reportedly cardioprotective effects of Adiponectin in mice require the presence of T cadherin ([@B40]).

Adiponectin Signaling Pathways {#S2.SS3}
------------------------------

Adiponectin through its receptors usually activates different molecular pathways. It is possible to distinguish the regulating pathways controlling metabolic functions or inflammatory/immune and proliferation processes. Indeed, the recent immune involvement of Adiponectin is to be attributed to presence of AdipoRs on surface of immune cells. Adiponectin activating AMP and P38 kinases in skeletal muscle and liver tissues, stimulates phosphorylation of acetyl coenzyme-A carboxylase (ACC) and PPAR-a, fatty acid oxidation, and glucose uptake. Through these pathways, Adiponectin mainly exerts its insulin-sensitizing actions ([@B70]; [@B172]).

In human monocyte-derived macrophages as well as in epithelial cells, Adiponectin induces an up-regulation of the anti-inflammatory cytokine IL-10 and interleukin-1 receptor antagonist (IL-1RA) expression ([@B172]). Furthermore, it inhibits the production of inflammatory cytokines and adhesion molecules reducing the inflammatory state in the various cellular models. This adipokine has been shown to inhibit tumor necrosis factor-α (TNF-α)-induced nuclear factor-kB activation in endothelial and epithelial cells. Moreover, Adiponectin seems to counteract cellular inflammation by affecting sphingolipid metabolism, since Adiponectin receptors display intrinsic ceramidase activity ([@B57]). On the vascular endothelium, in particular, Adiponectin also increases endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) production via the activation of AMPK signaling and phosphoinositide-3-kinase (PI3K)-Akt pathway ([@B57]; [@B155]).

Adiponectin Functions {#S2.SS4}
---------------------

Even if Adiponectin has been strongly associated with insulin-sensitizing effects, it is well described that Adiponectin explicates many other biological effects. Indeed, beyond the essential roles of Adiponectin in metabolic regulation, it has a role in several cellular processes such as proliferation, inflammation, and oxidative stress. Indeed, Adiponectin has many metabolic properties, being an insulin-sensitizing hormone, it stimulates glucose and fatty acids metabolism, it reduces liver production of glucose and increases GLUT-4 translocation in muscle cells. On the other hand, it is know that there is a strongly involvement of this adipokine also in inflammatory and immune responses. Adiponectin role in inflammatory processes is controversial because both pro- and anti-inflammatory actions have been found *in vitro* and *in vivo* studies ([@B89]; [@B120]; [@B159]; [@B46]; [@B25]; [@B163]; [@B63]). Furthermore, as reported by [@B128], in a cohort of Cystic Fibrosis (CF) patients, adiponectin is strongly correlated to severity of disease and it is modulated by physical activity. Indeed, the authors reported that in CF patients, physical activity improves respiratory functions, lipid metabolism, and inflammation status. All these improvements are associated with adiponectin ([@B128]). Several mechanisms have been implicated in the anti-inflammatory properties of Adiponectin: - to increase synthesis of IL-10 ([@B79]); -to promote macrophage polarization toward the anti-inflammatory M2 phenotype ([@B120]; [@B93]; [@B28]); - to reduce the expression of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-12; -to induce the anti-inflammatory cytokine IL-10 in M2 macrophages ([@B120]; [@B93]; [@B28]). In addition, a relevant biological role of Adiponectin has been recently highlighted in the immune system, where it functions as an immune-suppressor factor. Adiponectin directly targets the immune system, functioning as an immunomodulator. Indeed, several *in vitro* studies reported that Adiponectin acts as an immune suppressor molecule reducing T cell responsiveness, B cell lymphopoiesis, and TNF-α production, suppressing macrophage activation and proliferation ([@B93]). In support of this hypothesis, [@B28] recently demonstrated a mechanism of immune suppression mediated by Adiponectin based on the reduction of T cell transmigration across the endothelium, which is one of the mechanisms involved in tissue inflammation. Adiponectin activates plasma B cells and induces secretion of the B cell-derived peptide PEPITEM, which inhibits memory T cell migration ([@B28]). *In vivo* studies on APN KO mice confirmed that Adiponectin has immunosuppressive effects since these animals present an increase of anti-inflammatory cells and mediators as well as an alteration of M1 (increased TNF-α, and IL-6), and M2 markers, (decreased IL-10) ([@B120]). Finally, human studies have demonstrated a strong modulation of Adiponectin serum concentrations and its receptors in course of immune disorders, powerfully suggesting that Adiponectin has an active role in regulating immune responses ([@B31]; [@B41]; [@B123]; [@B81]; [@B128]). Furthermore, it is able to acts also in oxidative stress, indeed Adiponectin in a cancer cells model induces apoptosis and reduce proliferation by oxidative stress in a time- and dose-dependent manner ([@B157]). On the contrary, Adiponectin has anti-inflammatory action, also reducing oxidative stress through activation of sirtuins pathways. In particular, Adiponectin is a molecule that strongly activates AMPK via AdipoR1, which in turn activates Sirt1, implicated in oxidative stress and longevity. Therefore, the increase of AdipoR1 activity provides a Adiponectin potential strategy against oxidative stress ([@B151]). It is well know that the beneficial effects induced by exercise seem to be mediated by the activation of the AMPK pathway. In addition, Adiponectin acts on AMPK pathway and then this adipokine may be represented also a valid molecules that mimic the beneficial effect of exercise through activation of AMPK.

Adiponectin and Exercise {#S2.SS5}
------------------------

Thanks to its several positive effects on body composition, insulin sensitivity, blood glucose, and lipid levels, physical exercise is recognized as one of the most effective tools in the prevention and the therapy of metabolic diseases and cancer ([@B65]). Also, physical exercise exerts its beneficial effects through the secretion of different hormones/cytokines involved in many pathophysiological processes ([@B62]).

To date, the interconnection between exercise and Adiponectin levels is not entirely clear, and the literature data show contradictory results. Several studies have been performed concerning the change in Adiponectin levels due to exercise, even if these studies are heterogeneous. Notably, due to different methods of the studies and the individual characteristics of the subjects no general conclusion can be observed. For an interpretation of results, different variables have to be considered such as duration of the intervention (acute exposure vs. prolonged exercise interventions), types of exercise (cardiovascular or resistance training), intensity of exercise (low-, moderate-, or high-intensity training), but also the age and gender of the participants (adolescents vs. adults vs. older adults; male vs. female), their body mass (obese, overweight, and normal-weight participants), health status (healthy people, people with type II diabetes, people with metabolic syndrome, etc.) ([@B2]). In addition, in some studies the main variables such as duration and typology of intervention were analyzed separately and other studies take into account the genetic predisposition in the Adiponectin gene (ACDC) as a possible individual factor that could determine activities. Therefore, genetic variants in ACDC were analyzed concerning sports performance, even if no relevant correlation was found ([@B114]). In 2008, a systematic review by Simpson and Singh reported that acute exposure to a range of exercise intensities was not sufficient to have effects on Adiponectin levels: probably, a change in body composition is necessary for significant modifications in circulating Adiponectin levels ([@B145]). Other studies reported different results: for example, [@B118] found that the total Adiponectin concentration decreased at the end of high-intensity aerobic training but remained unchanged after moderate aerobic exercise in middle-aged abdominally obese men. The same authors indicated that the change in total Adiponectin was mainly due to the concentration changes of middle-- and low--molecular weight oligomers of Adiponectin during high-intensity aerobic training, whereas high-molecular oligomers did not change. Similarly, [@B92] found that no change occurred after a moderate endurance exercise in the concentration of total and high molecular weight Adiponectin in healthy adults, despite a significant improvement of insulin sensitivity ([@B54]; [@B95]; [@B110]). Furthermore, changes in Adiponectin levels was also observed in children with type 1 diabetes during acute exercise at moderate intensity ([@B96]).

On the contrary, [@B138] found that a non-usual aerobic exercise at both high and low intensities produced a significant increment of plasmatic Adiponectin levels immediately after the end of the exercise. Simpson and Singh also investigated the effects of chronic exposure to exercise on Adiponectin concentration ([@B145]). As for acute exercise, Adiponectin concentration remained the same in several uncontrolled trials as well as in the majority of the not randomized controlled studies. The randomized controlled trial results suggest that the influences on Adiponectin levels were probably mediated by the changes in body composition that exercise produced ([@B30]). This finding is partially in agreement with [@B146] who recently reported that plasma Adiponectin levels are negatively correlated with body fat percentage in older males, but not in older females; these results highlighted a possible gender-specific mechanism which may affect the association between Adiponectin and age-related body composition changes.

Overall, in the last few decades, only a few studies with correct approaches have been found. In these studies, both aerobic and resistance training improved Adiponectin levels in about one-third of trials performed on sedentary, overweight and obese people ([@B30]; [@B17]; [@B4]; [@B117]; [@B39]).

Endurance training was recently associated with increased insulin sensitivity without changes in circulating Adiponectin ([@B71]). Moreover, in endurance athletes, Adiponectin significantly increases during the race and recovery periods. In contrast, it was reported that running a marathon increases Adiponectin levels. Several studies were conducted to evaluate the effects of cardiovascular training, and in particular aerobic exercise, on Adiponectin plasma levels: the main results are summarized in [Figure 1](#F1){ref-type="fig"}.

![The major effects of Adiponectin induced by physical activity. The physical activity acts on adiponectin reducing oxidative stress and inflammation and inducing glucose up-take, fatty acid metabolism and osteogenesis by AMPK.](fphys-11-00356-g001){#F1}

[@B127] showed that 3 months of aerobic training did not produce changes in the adipose tissue or plasma levels of Adiponectin, leptin, interleukin 6, and tumor necrosis factor α in obese women, even if a reduction of body fat mass was reported. [@B113] also observed that there is not significant changes in overweight and obese girls; but in this case, the body fat mass did not reduce during the intervention. However, Simpson and Singh in their systematic review affirmed that it is possible to support the use of moderate or high-intensity resistance or aerobic exercise of adequate duration to produce substantive changes in body composition, increasing Adiponectin levels ([@B145]). In agreement with this assertion, recent investigations seem to confirm this theory. The data obtained by [@B112] suggest that aerobic training produces a higher increment of Adiponectin levels in trained, middle-aged, normal-weight females. These results were reported after long-term progressive training. Another recent intervention demonstrated that aerobic exercise training at high frequency (5 days/week) and high intensity (85% HR max), independently from diet, altered high molecular weight Adiponectin and leptin secretion, and that the reduction in visceral fat mass was the key factor to regulate Adiponectin levels in older obese subjects ([@B71]). These studies indicate that a significant volume of aerobic training is necessary to obtain a significant modification of Adiponectin levels and that this large volume can be reached both using long term interventions and high-intensity exercise protocols. Other authors recently confirmed the importance of prolonged exercise training (of at least moderate intensity) in order to obtain a significant increase in serum Adiponectin ([@B92]): in fact, it was demonstrated that 12 weeks of moderate aerobic training significantly improved the total serum Adiponectin and high molecular weight Adiponectin in people with diabetes type II who generally have low serum Adiponectin levels ([@B4]). Furthermore, recent studies show that adiponectin expression is modulated by long-term physical activity in patients affected by Cystic Fibrosis and that, interestingly, in the active group cystic fibrosis patients adiponectin levels were inversely correlated with forced expiratory volume (FEV) 1% decrease/year and FEV1% decrease ([@B128]).

In particular, another recent RCT study investigated the effects of aerobic training-detraining, concluding that 10 weeks of aerobic interval training was useful to significantly increase plasma Adiponectin levels in young male non-athletes whereas, the same subjects, after 4 weeks of detraining, showed a significant reduction of Adiponectin levels ([@B39]). Finally, [@B80] found that 6 months of chronic aerobic exercise alone or combined with diet produced a significant increment of circulating and adipose tissue Adiponectin levels in obese women independently from changes in body composition. In this case, the review of Simpson and Singh indicated that the positive effects of resistance training are probably mediated by changes in body composition, and the recent evidence of literature seems to confirm the possible effectiveness of this kind of exercise ([@B145]).

All these studies that found Adiponectin level changes independently from body composition changes (including the study with aerobic interventions), suggest that the circulating Adiponectin may be influenced by exercise also independently from body composition changes. Intermittent fasting programs in conjunction with resistance training improves some health-related biomarkers, among which Adiponectin. Thus, it may be stated that changes in fat mass could be only one way to influence Adiponectin levels, but other mechanisms can link exercise to Adiponectin levels ([@B47]; [@B92]). However, the effects of physical exercise on serum adiponectin levels are controversial, depending on the exercise type, the intensity of the training and the study population; some studies, performed on patients with obesity, diabetes and at high risk for myocardial infarction, showed a positive correlation between adiponectin levels and exercise, while others demonstrated that basal adiponectin concentrations do not change after long-term exercise ([@B130]). Furthermore, only a few studies examined the effects of exercise on the HMW oligomers ([@B95]). In addition, it is know that long-term physical activity induces improvements in body composition and energy metabolism. In addition, physical exercise ameliorates also inflammation and FEV1% decline in patients affected by Cystic Fibrosis as reported by [@B43]. Despite the controversial data regarding total and HMW adiponectin in physical activity, there is a mechanism by which adiponectin participates in exercise-induced anti-inflammatory functions and/or cardiovascular health, as suggest by the direct correlation of adiponectin with severity of diseases in cystic fibrosis that are strongly modulated by physical activity and also by the direct correlation of adiponectin with monocytes in water polo athletes by [@B114] and also reducing oxidative stress through activation of sirtuins pathways ([@B114]; [@B128]).

Physical Exercise and Bone Metabolism: The Role of Adiponectin {#S2.SS6}
--------------------------------------------------------------

Within the musculoskeletal system, bone represents a metabolically active tissue, continuously undergoing a remodeling process determined by osteoblasts and osteoclasts; in children and adolescents such processes cause an increase in body mineral content (BMC), and during adulthood it can reach the maximum peak bone mass ([@B12]; [@B49]).

The "physiology" of bone tissue is regulated by the surrounding organs such as adipose tissue, and their secreted circulating factors. Several experimental studies show that bone and adipose tissue are cross-regulated at multiple levels, leading to the concept of a bone-adipose axis ([@B135]; [@B150]). Indeed, osteoblasts and adipocytes co-exist in the bone marrow, sharing a common mesenchymal stromal cell progenitor; such a feature determines an inverse reciprocal relationship where specific signals can influence differentiation, promoting one phenotype and suppressing another ([@B119]; [@B50]; [@B51]). In this regard, [@B56] suggested that an osteoblast-adipocyte intermediate precursor might be generated in the lineage commitment process of mesenchymal progenitor cells, whereas [@B139] hypothesized that mature cells could dedifferentiate and transdifferentiation into the other phenotype.

Bone and adipose tissue act as endocrine organs on each other. In particular, the secretion of adipocyte-specific factors, such as adipokines, represents a main molecular mechanism by which adipose tissue acts on the bone. Osteoblasts and osteoclasts express Adiponectin and its receptors but, up to now, data related to Adiponectin effects on bone mass are confounding ([@B12]; [@B144]). *In vitro* studies show that osteoblasts and osteoclasts are direct and indirect targets of Adiponectin, respectively. Exogenous Adiponectin stimulates human osteoblast proliferation and differentiation, via the MAPK signaling pathway, whereas it simultaneously contributes to osteoclast formation ([@B121]; [@B90]). [@B144] suggest a distinct influence of Adiponectin on osteoblasts, and consequently, on osteogenesis, depending on the mode of action; indeed, in an autocrine/paracrine fashion Adiponectin would favor bone formation, while in an endocrine mode of action it would act against bone growth. *In vivo* studies demonstrated that Adiponectin-deficient mice have either normal or increased bone mass ([@B167]; [@B135]).

Bone mineralization and turnover are also affected by physical exercise; in fact, the type, intensity, and duration of mechanical loading on bone have great effects on skeletal development and strength ([@B131]; [@B88]). Several studies associate circulating levels of Adiponectin with bone mineral content (BMC) and/or body mineral density (BMD) in subjects of different ages and showing a different level of physical fitness. In a longitudinal study performed for 12 months on healthy physically active postmenopausal women, [@B67] observed an increase in plasma Adiponectin levels in relation to a decrease in BMD, indicating a role of Adiponectin in a body mineral setting. A similar result was found in untrained post-menopausal women after a 12-month long study ([@B111]). Likewise, Adiponectin was considered a negative independent predictor of lumbar spine BMD in healthy or obese untrained girls ([@B105]; [@B67]; [@B134]; [@B103]). Generally, Adiponectin levels in athletes are high, and they are stable under intense training conditions and low energy states ([@B66]); in a cross-sectional study performed on adolescent girls comparing the effects of neuroendocrine factors, such as peptide YY and Adiponectin, on amenorrhea endurance athletes, on eumenorrheic endurance athletes, both under lower energy availability, and on eumenorrheic non-athletes, [@B133] found that high peptide YY levels, but not Adiponectin, was a predictor of hypogonadism and impaired bone metabolism in amenorrhea athletes. In adolescent trained girls, bone mineralization is positively influenced by bone-loading sport with a high impact, such as rhythmic gymnastics, despite the increased levels of Adiponectin and sclerostin (a hormone inhibiting osteogenesis) compared to an untrained age-matched control group ([@B68]); moreover, these authors found a positive correlation between sclerostin and Adiponectin in untrained controls, suggesting, even more, the metabolic interplay between bone and adipose tissues. Moving to female prepubertal rhythmic gymnasts (7--9 years), [@B173] found that the athletes showed higher BMD parameters and lower fat mass values compared to untrained controls, but plasma Adiponectin levels were not related to total or areal BMD, suggesting that specific physical activity patterns are beneficial to bone mineralization ([@B68]; [@B20]).

Subjects participating in endurance exercises characterized by no weight-bearing activities, such as running, cycling, or swimming, have lower BMD values in comparison to both age-matched power-trained peers and untrained controls ([@B88]). Interestingly, the Adiponectin levels in trained male rowers increase, supporting the inverse correlation with BMD and the hypothesis that Adiponectin may be a metabolic signal of energy needs associated with acute endurance exercise ([@B68]).

Overall, the Adiponectin response to physical exercise in relation to bone metabolism may depend on age, exercise training intensity, and energy availability/needs. Besides Adiponectin concentrations, it cannot be excluded that complex interactions between different factors such as bone load, body composition, and energy/metabolic status, contribute to bone metabolism. The reported data certainly suggest an action of Adiponectin on bone metabolism through a paracrine/autocrine mechanism, but not a predictive role of Adiponectin as a marker of bone mass mineral content/density or turnover ([@B91]; [@B69]; [@B156]). Furthermore, previous studies found that the moderate physical exercise might regulates bone remodeling through osteocytes. It was reported that exercise prevents osteocyte apoptosis and improves some of the microarchitectural parameters, increases bone mineral density and osteocyte lacunar occupancy. On the other hand, as reported by [@B173], adiponectin deficiency triggers osteoporosis-like features, accompanied by increased osteoclastogenesis, increased adipogenesis, and decreased osteogenesis ([@B173]). Importantly, these findings to indicate that adiponectin regulates functions of bone cells and then may be a role in beneficial effects of physical activity on bone marrow.

The Orexin-A {#S3}
============

Orexin-A: Structural Characteristics {#S3.SS1}
------------------------------------

The neuropeptide Orexin-A (hypocretin-1) is secreted by neurons in the lateral hypothalamus ([@B76]). This neuropeptide is an important link between peripheral energy balance and the CNS mechanisms that coordinate sleep-wakefulness and motivated behaviors such as food-seeking, especially in the physiological state of fasting stress ([@B77]). The orexin system is composed of two G-protein coupled receptors, the orexin-1 receptor (Ox1) and the orexin-2 receptor (Ox2) and two neuropeptides, Orexin-A and orexin-B ([@B16]). Orexin A is composed of 33 amino acids with an amino(N)-terminal pyroglutamyl residue, two intra-chain disulfide bonds and carboxy (C)-terminal amidation. The N-terminal portion presents more variability and it characterized different orexins (A and B), whilst the C-terminal portion is similar between the two subtypes. Orexin activity is modulated by their specific receptors (OX1R and OX2R) ([@B78]). The orexin system is functionally related to physiological processes such as reward-seeking behavior, energy homeostasis, sensory modulation, stress processing, or locomotion, cognition, and endocrine functions. In addition, modulation of the orexin system could have a potential impact on various pathophysiological disorders including disturbances of the sleep-wake cycle, addiction, feeding disorders, stress and anxiety disorders or pain ([@B171]; [@B137]).

Orexin-A Receptors {#S3.SS2}
------------------

Orexins have many functions binding their receptors. In particular, Orexin-A binds both OX1R and OX2R with high affinity, while Orexin-B displays more selectivity. Orexin peptides interact with their receptor binding the transmembrane domains 1, 3, and 5 and the amino terminus of the receptors. Furthermore, it is noticeable that both OX1R and OX2R exhibit slow kinetics in their response to orexin binding. OX1R expression is in the cortical regions and brainstem nuclei, mainly involved in sleep and wake regulation as well as nuclei involved in reward signaling ([@B16]). OX1R couples with Gq and induces intracellular calcium elevation mediated by phospholipase C (PLC) and also couples with Gs and Gi to mediate cAMP levels and non-selective cation channels ([@B5], [@B6]; [@B171]; [@B164]). OX1R signaling has been implicated in feeding, water intake, spatial learning and reward pathways ([@B7]). OX2R is expressed only or mainly in histaminergic neurons, serotonergic neurons in the brainstem, the nucleus accumbens, the septal nuclei and the striatal nuclei, which mainly promote arousal ([@B23]). OX2R is activated by both orexins A and B. Orexins and their receptors are also expressed peripherally, although at relatively low levels. Furthermore, pre pro-orexin and OX1R mRNA are found in the adrenal glands, testes and jejunum, high levels of orexins and OX2R mRNA in the adrenal cortex, and both receptor mRNAs in adipose tissue, myenteric plexus of the small intestine, pancreas as well as in the retina ([@B5], [@B6]; [@B171]; [@B164]). Given the presence of its receptors in various organs and tissue, Orexins have pleiotropic effects and endocrine, paracrine and neurocrine roles in numerous organs and tissues ([@B7]; [@B23]).

Orexin-A Signaling Pathways {#S3.SS3}
---------------------------

Binding its receptor, Orexin-A induced a variety of downstream signaling mechanisms. Indeed, the binding causes changes in the structure of the receptor, starting a protein kinase C (PKC)-mediated influx of calcium. When Ca^2+^ channel is activated, trigger many other signal pathways, including activation of mitogen-activated protein kinase (MAPK), that regulates ERK, p38, cAMP- adenylyl cyclase (AC), and PLC. Intracellular calcium stores are released by a PLC mediated pathway, producing sustained excitation of related neurons ([@B169]). Signaling from OXR to ERK phosphorylation (activation) via PKC, PI3K, Ras, and Src has been extensively explored ([@B78]). Furthermore, Orexin-A, binding its receptors, produces a transient ERK1/2 activation through Gq/PLC/PKC, Gi, and Gs/AC/cAMP/PKA cascades. A global gene expression profile was applied to identify gene transcription in response to OX1R ([@B7]). This data indicated that the OX1R regulated genes are involved in cell growth (30%) and metabolism (27%), of which TGF-β/Smad/BMP, FGF, NFkB, and hypoxic signaling pathways were the most prominent ([@B104]). Given the multiple physiological processes and second messenger pathways potentially activated by orexin, it is not surprising that Orexin-A has pleiotropic effects ([@B165]). It is well known that the activation of OX1R/OX2R by Orexin-A alters proteins involved in intracellular metabolic function ([@B78]). The *in vitro* study suggests that Orexin-A activation of MAPKs might represent one link between orexin and cellular mechanisms mediating long-term energy balance. In particular, in the literature, it is reported that Orexin-A can activate MAPKs, and several studies have shown that increased MAPK activity is correlated with increased obesity resistance ([@B165]).

Data in the literature reported that orexin MAPK pathways involve PGC-1α, a tissue-specific and inducible transcriptional coactivator for several nuclear receptors. However, whether PGC-1α is a critical component of orexin effects on neuronal metabolism remains to be explored ([@B64]). This cofactor is also known to play key roles in energy metabolism, hepatic gluconeogenesis, and cholesterol homeostasis. Alterations in PGC-1α are associated with different pathologies such as obesity, diabetes, and chronic neurodegenerative diseases ([@B64]). Orexin-A has been shown to be neuroprotective in the cerebral cortex and in hypothalamic cell culture following oxidation, potentially through activation of HIF-1α through PGC-1 α ([@B104]). In addition, these findings suggest that Orexin-A effects on HIF-1α could represent another link between orexin and cellular metabolic signaling pathways relevant to obesity. It has been demonstrated that Orexin-A induces HIF-1α expression in hypothalamic tissue *in vitro*, increasing ATP production via oxidative phosphorylation ([@B104]; [@B78]; [@B165]). Furthermore, data in the literature, suggest that Orexin-A effects HIF signaling cascades could alter central mechanisms of energy expenditure in response to various metabolic stressors such as high-fat diets.

Orexin-A Functions {#S3.SS4}
------------------

Orexin-A activity is influenced by a series of metabolic molecules such as glucose, leptin and amino acids and by environmental factors such as the levels of activity in the neurons producing orexin increase during the waking phase of the circadian cycles and fasting or periods of caloric restriction. These neurons regulate physiological and behavioral processes that have an essential impact on energy balance and metabolic status, physical activity, blood glucose levels, and food intake ([@B64]). For these reasons, the most reliable hypotheses propose that the neurons located in the lateral hypothalamus regulate gratification behaviors, while those of the perifornical and dorsomedial areas are involved in excitement and stress. Since Orexin-A modulates energy metabolism, excitement, and physical activity, it plays a role in countering obesity, increasing spontaneous physical activity (SPA) and energy expenditure. Mouse models with mice without a functioning Orexin-A system become obese, consuming fewer calories compared to the wild-type. The accumulation of unhealthy weight in these animals is probably due to an energy imbalance caused by reduced physical activity ([@B27]).

On the other hand, after Orexin-A injections, particularly in the rostral lateral hypothalamus, subjects have lost weight and have developed a higher propensity to the SPA, energy expenditure, and regulation of food intake ([@B26]). There is a sure connection between orexin signals, the SPA and thermogenesis making this transmitter an exciting element for the fight against obesity ([@B154]). Furthermore, the authors reported that among the mice raised on a high-fat diet, those with a better response to Orexin-A stimuli gained more weight and did not decrease the rate of SPA carried out after weight accumulation. These data suggest that a high reaction to orexin increases resistance to obesity induced by diet and that the transmitter can regulate energy expenditure through the SPA and its thermogenesis. In obese humans, a shortage of circulating Orexin-A levels and a diminished response of its receptors in fatty tissues have been noted, but due to the lack of studies, we are not yet able to understand the different influence of individual responses to Orexin-A environmental factors such as a high-calorie diet and a sedentary lifestyle in the development of obesity, but we certainly know that physical activity is able to improve the clinical results in the treatment of this condition even in old age ([@B55]). Furthermore, the orexin neurons are involved in body weight gain via the interactive effects of exercise and diet, with each orexin receptor playing a unique role. These studies suggest that orexin functions as a regulator of obesity. Overall, it is well know that orexin-A regulates insulin sensitivity, energy expenditure and metabolic rate and is involved in immune processes and then regulate inflammatory response, with an anti-inflammatory action. For these reasons, the production of orexin-A by correct nutrition and by physical activity, has an important role in prevention of metabolic and inflammatory disease and also of the aging ([@B108]).

Orexin A and Physical Activity {#S3.SS5}
------------------------------

Physical activity may improve general health, preventing obesity and reducing cognitive decline associated with age. Exercise is a necessary part of a healthy lifestyle but many people cannot or do not want to do it, thus alternative solutions are being sought to achieve and maintain a healthy weight. SPA is an excellent candidate, but we do not yet have sufficient knowledge of the brain mechanisms that regulate it. Therapies aimed at increasing physical activity would contribute to better clinical outcomes in the treatment of obesity and metabolic syndrome, high-incidence diseases in developed countries ([@B124]). Current research is specifically investigating changes in the neuropeptide Orexin-A during normal and pathological aging. The Orexin-A signaling system regulates a series of complex behaviors, including sleep/wake, gratification, food intake, and SPA, with a general effect on energy expenditure.

[@B55] reported that Orexin-A levels were associated with the increased risk of becoming overweight and obese, independently from physical activity and sedentary time. [@B76] injected Orexin-A into three brain projection sites of SD rats and found increasing ambulation and less time spent in the sedentary position. This finding is important and consistent to conclude that Orexin-A increases physical activity and reduces sedentary time. In addition, the plasma Orexin-A level was associated with physical activity in obese and overweight people, including many aspects of daily life, such as working, domestic work, and especially walking. A high Orexin-A level was related to moderately active movement in living habits ([Figure 2](#F2){ref-type="fig"}).

![Physical activity increases Orexin-A levels with various beneficial effects. The Orexin-A levels induced by physical activity has many beneficial effects, its decreases body weight and inflammation, and increases energy expenditure, cognitive performance and metabolic rate.](fphys-11-00356-g002){#F2}

The higher Orexin-A tone is an endogenous factor that predicts physical activity, improving BMI and the energy expenditure aspect. In addition, literature data suggest that Orexin-A might be a new potential therapeutic method for controlling obesity by regulating physical activity and energy expenditure. It is well known that physical activity has positive effects on health and body weight ([@B77]; [@B176]). In addition, it improves cognitive performance ([@B34], [@B33]; [@B84]; [@B44]). [@B83] reported that this is a two-way interaction, as choices made throughout life and aging, either directly or indirectly, impact physical activity levels. In the current climate of rising obesity trends, a great deal of attention has been given to the deleterious effects of sedentary lifestyles on body weight and overall health ([@B83]). Several experimental works suggest that obese individuals spend significantly less time in physical activity. Lean people spend an extra 150 min per day moving compared to obese people, while obese patients sat for 2 h longer per day than lean individuals ([@B82]). The question then becomes, in which manner brain mechanisms can contribute to obesity, regulating physical activity levels. As suggested by [@B77], different lines of evidence support orexin peptides as key modulators of physical activity, especially in response to nutrition levels and energy availability. In fact, the orexin system is well placed to both modulate and be influenced by the metabolic state. Overall, orexin signaling is suppressed in an obese state ([@B73]; [@B125]). Furthermore, [@B109] reported that caloric restriction, as occurs during food deprivation in animals or dieting in humans, increases orexin mRNA and orexin receptor expression ([@B74]; [@B3]). In addition, [@B52], support the idea that orexin neurons act as adaptive glucose sensors and are inhibited directly at higher glucose concentrations, suggesting that hyperglycemia results in decreased orexin signaling ([@B18]; [@B168]; [@B52]). This would promote lower SPA and energy expenditure, contributing to the development of obesity, but the authors did not report electrophysiological studies comparing orexin neuron activity in lean and obese states. As reported by [@B126], it must be emphasized that orexin neurons are part of a local (intra- hypothalamic) and global (across the brain) network involved in the control of behavior and energy balance ([@B19]). Thus, when considering specific mechanisms that contribute to obesity, orexin signaling is only one part of an interconnected system influenced by multiple genetic and environmental factors, such as energy expenditure and physical activity. As reported by [@B86], Orexins regulate a variety of physiological functions in the body by activating phospholipase C/protein kinase C and AC/cAMP/PKA pathways. Furthermore, this peptide has critical functions in energy metabolism, regulating both feeding behavior and energy expenditure. Increasing the sensitivity of orexin- coupled hypothalamic neurons concurrently enhances spontaneous physical activity, non-exercise activity thermogenesis, white adipose tissue lipolysis, and brown adipose tissue thermogenesis.

Physical Exercise and Bone Metabolism: The Role of Orexin-A {#S3.SS6}
-----------------------------------------------------------

Bone remodeling in the adult skeleton of vertebrates is a continuous and dynamic process. It is tightly coupled to osteoblast-mediated bone formation with osteoclast-mediated bone resorption. Osteoblasts are derived from bone marrow mesenchymal stem cells (MSCs) that can also differentiate into marrow adipocytes, the balance of which is controlled by different hormones and transcription factors ([@B13]; [@B162]; [@B32]; [@B106], [@B107]). On the contrary, osteoclasts are differentiated from macrophage precursors in response to the Receptor Activator of the NFκB Ligand (RANKL), depending on the ratio of RANKL to OPG (osteoprotegerin), a RANKL decoy receptor that inhibits osteoclast differentiation ([@B116]). Furthermore, there is evidence that neuropeptides, such as neuromedin U (NMU) and neuropeptide Y (NPY), modulate skeletal homeostasis through both central and peripheral functions ([@B132]). Furthermore, it is reported that OX1R expression was suppressed during osteoblast differentiation but elevated during adipocyte differentiation. Again, OX2R was not expressed in either culture. Marker gene expression confirmed complete differentiation. This indicates that OX1R may be pro-adipogenic and anti-osteoblastogenic. On the one hand, orexin activation of OX2R in the brain centrally enhances bone formation by lowering circulating leptin levels ([@B15]). On the other hand, orexin activation of OX1R in the bone locally suppresses bone formation and enhances bone resorption by lowering osseous ghrelin expression. Importantly, the central action is dominant over local action so that systemic orexin over-expression increases bone mass whereas complete deletion of orexin or orexin receptors decreases bone mass. It is remarkable how orexin achieves a physiological balance in the regulation of skeletal homeostasis by differentially utilizing two different receptors at distinct anatomic sites.

In addition, in a mouse model, orexin neurons are also maximally active during the performance of rewarded behaviors; OX1R/2R-KO mice are deficient in conducting rewarded behaviors; and OX2R-KO mice display increased behavioral despair, indicating a similar involvement of orexin in positive reinforcement ([@B15]; [@B98]; [@B141]). Other studies conducted on humans demonstrated that depression is associated with low bone mass, increasing the incidence of osteoporotic fractures ([@B9]). In a mouse model, depression induces bone loss by inhibiting bone formation via the stimulation of the sympathetic nervous system ([@B174]). Moreover, [@B177] reported that *in vivo* genetic studies using OX1R KO mice, in combination with *in vitro* bone marrow osteoblast differentiation assays using orexin peptides and orexin receptor inhibitors, demonstrated that OX1R suppresses osteoblast differentiation and bone formation. Furthermore, the same authors reported that the central action is dominant over the peripheral action because bone mass is reduced in orexin-null and OX1R/2R-double-null mice but enhanced in orexin over-expressing transgenic mice. These findings showed that orexins play a pivotal role in skeletal homeostasis, exerting a yin-yang dual regulation, and highlighting a therapeutic role for several diseases, such as osteoporosis.

Discussion {#S4}
==========

The positive effects of physical exercise on body composition, insulin sensitivity, and blood glucose levels have been demonstrated in multiple physiological and pathophysiological conditions ([@B44]). Physical activity improves general health, preventing obesity and reducing cognitive decline associated with age. It is a necessary part of a healthy lifestyle having beneficial effects on various organs and tissue ([@B65]). The physical exercise reduces the chronic inflammation and oxidative stress both in physiological and in pathophysiological state such as cystic fibrosis ([@B43]) and also it induces molecular mechanism acting on adiponectin serum levels, on pro-inflammatory cytokines, orexin-A serum levels and other mediators. An adequate Adiponectin serum levels are important to maintain and/or obtain the beneficial effects due to this adipokine and of a wellness state. Extremely elevated Adiponectin serum levels have been associated with an increase in mortality in subjects with or without CVD, heart failure, or atrial fibrillation ([@B2]). Similarly, the obesity paradox has been described to indicate that overweight or obese individuals affected by several diseases (COPD, CVDs) may have lower mortality compared with normal-weight individuals, events associated with high Adiponectin levels ([@B115]). On the other hand, low Adiponectin levels -- reduced with respect to the normal range -- clearly are associated with detrimental effects in terms of energetic metabolism as well as in inflammatory processes and cancer ([@B129]). Obesity, insulin resistance, high-fat diet, and sedentary lifestyle are associated with a decrease in Adiponectin serum levels ([@B1]). Therefore, to choose activities that physiologically increase serum Adiponectin levels represent a valid strategy to achieve and maintain a healthy status. There are some approaches seem to be desirable and applicable: healthy diet and physical exercise. Both agonists of AdipoR1/R2, as well as strategies to increase AdipoR1/R2 action, may be a logical approach to provide a novel treatment modality for metabolic and inflammatory diseases ([@B115]). Orexins were initially reported to be regulators of feeding behavior based on their capacity to elicit food intake when centrally administered to rats. Many studies have subsequently replicated this effect in mice, and even in zebrafish ([@B26]).

Conversely, intraventricular administration of an anti-orexin antibody or an OX1R antagonist, as well as genetic ablation of orexin neurons, attenuates food consumption. One of the mechanisms by which orexins induce food intake is the activation of neurons in the arcuate nucleus expressing neuropeptide Y, a peptide known for its orexigenic effects. Orexin neurons are able to monitor humoral and neural indicators of energy balance. High extracellular levels of glucose and leptin, a hormone from adipose tissue reducing food intake, inhibit the activity of orexin neurons. On the contrary, decreased concentrations of glucose or ghrelin, a fasting-induced hormone secreted by the stomach, activate orexinergic cells. Food deprivation induces the expression of pre-pro-orexin in the hypothalamus, as well as raising OX1R and OX2R mRNA levels in diverse brain regions ([@B171]). These findings suggest that orexin neurons monitor indicators of the energy balance of the body and mediate adaptive augmentation of arousal, and, in turn, of feeding behavior in response to fasting. Interestingly, orexin- neuron ablated mice, despite exhibiting hypophagia, display an obese phenotype, and narcoleptic humans have an increased body mass index although their caloric intake is lower. A possible explanation for these observations emerges from studies indicating that orexins also contribute to increase body energy expenditure. Thus, the central administration of Orexin-A has been reported to increase energy consumption by increasing spontaneous physical activity and thermogenesis. Moreover, orexin overexpressing mice have been reported to be resistant to diet-induced obesity. Therefore, orexin signaling might positively regulate feeding and arousal, but also motor activity and basal energy expenditure, resulting in resistance to weight gain ([@B26]). Furthermore, the Orexin-A level is correlated with physical activity and low sedentary time. Indeed, the plasma Orexin-A level is associated with physical activity in obese and overweight people, including many aspects of daily life, such as working, domestic work, and walking especially. A high Orexin-A level is related to moderately active movement in living habits. Higher Orexin-A tone is an endogenous factor that predicts physical activity, improving BMI and energy expenditure ([@B26], [@B27]).

Overall, the Adiponectin and Orexin-A have similar effects on different diseases and also on healthy status. Indeed both these proteins are involved in the same metabolic pathways, increasing metabolic rate and energy expenditure, acting on bone formation and metabolism. Furthermore, Adiponectin and Orexin-A are involved in inflammatory and immune processes ([Figure 3](#F3){ref-type="fig"}).

![The interplay between Adiponectin and Orexin-A in physical activity: Adiponectin and Orexin-A are differently expressed during physical activity, but there is a strong interconnection between these two peptides. Both regulate bone metabolism, increase energy expenditure and metabolic rate, ameliorating lipid profile and reducing inflammation state.](fphys-11-00356-g003){#F3}

Given these similar actions, there may be a possible interplay between these two molecules, leading an improvement of lifespan and aging.

In conclusion, both the increase of Adiponectin and Orexin-A concentrations corresponds to the improvement of wellness and may be a new potential therapeutic method for controlling obesity by regulating physical activity and energy expenditure.
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